Impact of the M22-IPL Acne Filter on Acne Vulgaris

NCT ID: NCT02180282

Last Updated: 2017-01-26

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-07-31
• Study Completion Date: 2015-12-31

Brief Summary

Up to 20 healthy subjects age 15-45 years old ,Skin Phototype I-V,Study will be conducted in 1 site.

Primary objectives is to evaluate the efficacy of IPL acne filter treatment for improvement of acne vulgaris as assessed by lesion count.

.

Conditions

Acne

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Acne Treatment

Acne treatment using the M22-IPL acne filter

Group Type: EXPERIMENTAL

M22-IPL

Intervention Type: DEVICE

The M22 is an advanced computer-controlled light emission system that incorporates several different light modules.

The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filter that will be used for this evaluation is the Acne Filter that cuts off all light with the wavelength of 400-600 and 800-1200nm.

Interventions

M22-IPL

The M22 is an advanced computer-controlled light emission system that incorporates several different light modules.

The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filter that will be used for this evaluation is the Acne Filter that cuts off all light with the wavelength of 400-600 and 800-1200nm.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Able to read, understand and provide written Informed Consent;

2. Healthy male or female, 15-45 years of age;

3. Fitzpatrick skin type I-V;

4. Have at least 15 inflammatory lesions (papules and pustules) in the face.

5. Having clinical diagnosis of mild to moderate inflammatory acne on face with Investigator Global Acne scale = 2 and 3;

6. Able and willing to comply with the treatment/follow-up schedule and requirements;

7. Women of child-bearing age are required to be using a reliable method of birth control (such as an intrauterine device, birth control pills, condom with spermicidal, Nova ring, and partner with vasectomy or abstinence) at least 3 months prior to enrollment and throughout the course of the study.

Exclusion Criteria

1. Skin type VI;

2. Pregnant, intending to become pregnant during the course of study, less than 3 months postpartum or less than 6 weeks after completion of breastfeeding;

3. Heavy smoker (>1 pack of cigarettes a day);

4. Unable or unlikely to refrain from tanning, including the use of tanning booths, during the course of the study;

5. Photosensitivity or any sensitivity to the sun that causes a rash or allergic reaction;

6. Use of photosensitive medication for which light exposure is contraindicated;

7. Treatment with topical retinoid therapy or antibiotics for the treatment of acne within 2 weeks of study enrollment or during the study.

8. Treatment with oral retinoid medications (Accutane® or Soriatane®) within 6 months of the study enrollment or during the study.

9. Treatment with any topical or systemic anti acne therapy for at least 2 weeks prior to starting the study treatment or during the study.

10. Any history of gold therapy;

11. Prior use of collagen, fat injections or other methods of skin augmentation (enhancement with injected or implanted material) in treated area within 12 months of initial treatment or during the course of the study. Treatment may not be performed at all over permanent dermal implants;

12. Prior ablative resurfacing procedure or face lift in treated area with laser or other devices within 12 months of initial treatment or during the course of the study;

13. Any other surgery in treated area within 9 months of initial treatment or during the course of the study;

14. Participation in a study of another investigational device or drug involving the same anatomical site within 3 month prior to enrollment or during this evaluation, or if not involving the same anatomical site, as per the Investigator's discretion;

15. History of keloid or any other type of hypertrophic scar formation or poor wound healing in a previously injured skin area;

16. Showing symptoms of hormonal disorders, as per the Investigator's discretion (such as Melasma, Chloasma);

17. Concurrent inflammatory skin conditions, Open laceration or abrasion of any sort on area to be treated during the course of treatment;

18. Active Herpes Simplex at the time of treatment or having experienced more than three episodes of Herpes Simplex eruption within a year of study enrollment;

19. Having a bleeding disorder or taking anticoagulation medications, including heavy use of aspirin, in a manner which does not allow for a minimum 10 day washout period prior to each treatment (as per the patient's physician discretion);

20. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications;

21. Having any form of active cancer at the time of enrollment and during the course of the study or history of skin cancer on the face;

22. Mentally incompetent or evidence of active substance or alcohol abuse;

23. Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study;

24. For subjects undergoing test spots: considerable undesired response consisting of skin hypopigmentation (long term whitening), a scar or pre scar formation or any response deemed by the Investigator as grounds for exclusion.

• Minimum Eligible Age: 15 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Lumenis Be Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dr. J. Matthew Knight, MD, FAAD

Role: PRINCIPAL_INVESTIGATOR

Knight Dermatology Institute

Locations

Knight Dermatology Institute

Orlando, Florida, United States

Countries

United States

Other Identifiers

LUM-ABU-M22-IPL-14-01

Identifier Type: -

Identifier Source: org_study_id